d. dimitriadis · baseline demographics december 2009 to february 2011 n=234 age (yrs) 64.4 ±11.3...
TRANSCRIPT
![Page 1: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/1.jpg)
Early Clinical Experience of Promus Element
Stent in Real World patients
TCT MEDITERRANEAN
TRANSCATHETER CARDIOVASCULAR
THERAPEUTICS MEDITERRANEAN
MAY 4-5, 2012
LIMASSOL, CYPRUS
EUROMEDICA-KYANOUS STAVROS, THESSALONIKI
D. DIMITRIADIS
![Page 2: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/2.jpg)
![Page 3: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/3.jpg)
![Page 4: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/4.jpg)
![Page 5: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/5.jpg)
Rationale for the PROMUS™ Element™ Stent
![Page 6: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/6.jpg)
![Page 7: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/7.jpg)
![Page 8: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/8.jpg)
![Page 9: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/9.jpg)
![Page 10: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/10.jpg)
![Page 11: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/11.jpg)
![Page 12: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/12.jpg)
![Page 13: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/13.jpg)
![Page 14: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/14.jpg)
![Page 15: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/15.jpg)
![Page 16: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/16.jpg)
![Page 17: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/17.jpg)
![Page 18: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/18.jpg)
![Page 19: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/19.jpg)
![Page 20: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/20.jpg)
![Page 21: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/21.jpg)
![Page 22: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/22.jpg)
![Page 23: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/23.jpg)
![Page 24: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/24.jpg)
Experience With Promus Element™ Stent at
Euromedica-kyanous Stavros Hospital
![Page 25: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/25.jpg)
Baseline DemographicsDecember 2009 to February 2011 n=234
Age (yrs) 64.4±11.3
Males 181 (77%)
Diabetes Mellitus 55 (23.5%)
Hypertension 132 (56.4%)
Hyperlipidemia 99 (42.3%)
Active Smokers 73 (31.2%)
Old CABG 27 (11.5%)
Old PCI 31 (13.2%)
![Page 26: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/26.jpg)
Lesion Characteristics
Number of Vessels 362
Mean number of vessel treated per patient 1.56±0.67 (range 1 to 3)
Number of lesions 445
Mean number of lesion treated per patient 1.9± 0.95 (range 1 to 5)
Location of lesion:
LAD 162 (36.4%)
RCA 142 (31.9%)
Cx 121 (27.2%)
LM 12 (2.7%)
Inter 4 (0.9%)
SVG 4 (0.9%)
![Page 27: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/27.jpg)
ANGIOGRAPHIC CHARACTERISTICS
Bifurcation 41 (9.2%)
CTO 27 (6.1%)
FMJ (>50mm) 35 (7.9%)
Small vessel (<2,5mm) 76 (17.1%)
LM 12 (2.7%)
SVG 4 (0.9%)
Calcification 55 (12.3%)
AMI 10 (4.3%)
3VD 23 (9.2%)
![Page 28: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/28.jpg)
Technical and Procedural Characteristics
(N= 234 Patients N= 445 Lesions)
Total number of Stents 513
Mean number of Stents per patient 2.19±1.14 (range 1 to 5)
Mean number of Stents per Vessel treated 1.42
Mean number of Stents per lesion treated 1.20
Mean stent length per patient (mm) 48.84±26.05 (range 12 to128)
Mean stent length per vessel treated(mm) 31,57
Mean stent length per lesion treated(mm) 25,68
Mean stent diameter (mm) 2.88±0.45
Post-dilatation (%) 93
Technical success a (%) 100
Procedural success b (%) 100
a: Successful delivery & deployment of study stent to the target vessel, without balloon rupture or stent embolization (per stent); b:
Mean lesion diameter stenosis <30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital MI, TVR or cardiac
death
![Page 29: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/29.jpg)
Clinical Outcomes At Mid Term FU (9.3±
3.2months)All -cause death, MI, TVR 10 (4.3%)
All -cause death 7 (3%)
cardiac 4 (1.7%)
Related to the TV 3 (1.3%)
Not related to the TV 1 (0.4%)
non-cardiac 3 (1.3%)
Myocardial infarction 0 (0%)
Target vessel revascularization (TVR) 3 (1.3%)
Target lesion revascularization (TLR) 2 (0.9%)
TLR, PCI 1 (0.4%)
TLR, CABG 1 (0.4%)
Non-TLR TVR, overall 1 (0.4%)
Stent thrombosis (ARC def/prob) 1 (0.4%)
Target lesion failure 6 (2.6%)
![Page 30: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/30.jpg)
Comparison of procedural CharacteristicsPlatinum
workhorse
RCT
Promus
Element
(N=768pts)
NUHC,
Singapore
Promus
Element
(N=208pts)
Kyanous
Stavros Greece
Promus
Element
(N=234pts)
Rotterdam
Promus/Xience
(N=649)
Mean number of lesion
treated per patient
1.11± 0.31 1.25± 0.57 1.9± 0.95 1.8± 1.0
Mean number of Stents
per patient
1.16± 0.44 1.55± 0.83 2.19±1.14 2.1± 1.4
Mean stent length per
patient (mm)
20.5± 7.0 28.55±13.64 48.84±26.05 57± 26
Mean stent diameter
(mm)
3.09±0.45 2.77±0.36 2.88±0.45 3.1± 03
More complex patients
![Page 31: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/31.jpg)
Comparison of Clinical Outcomes At Mid Term FU
Platinum
workhorse
RCT
Promus
Element
(N=768pts)
NUHC,
Singapore
Promus
Element
(N=106pts)
Kyanous
Stavros
Greece
Promus
Element
(N=234pts)
Rotterdam
Promus/
Xience
(N=636pts)
All -cause death, MI, TVR 5.0% (37) 2.8% (3) 4.3% (10) 12.1%
All -cause death 1.3% (10) 1.9% (2) 3.0% (7) 7.2%
Myocardial infarction 1.1% (8) 0.0% (0) 0.0% (0) 1.8%
Target vessel revascularization
(TVR)
2.7% (20) 1.0% (1) 1.3% (3) 4.3%
Target lesion revascularization
(TLR)
1.9% (14) 1.0% (1) 0.9% (2) 2.8%
Target lesion failure 3.5% (26) 0.9% (1) 2.6% (6)
Stent thrombosis (ARC def/prob) 0.4% (3) 0.0% (0) 0.4% (1) 0.6%
More complex patients
![Page 32: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/32.jpg)
CASE 01: Tortuosity
Excellent deliverability: Direct stenting 3.0X38mm !!!!!!
![Page 33: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/33.jpg)
Excellent
conformability!!!!
![Page 34: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/34.jpg)
CASE 02: Bifurcation-Mini Crush
![Page 35: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/35.jpg)
3.0X32mm
2.75X28mm
Kissing
balloon
![Page 36: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/36.jpg)
FINAL RESULT
![Page 37: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/37.jpg)
9 MONTHS FOLLOW-UP
![Page 38: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/38.jpg)
CASE 03: AMI-3VD PCI
![Page 39: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/39.jpg)
![Page 40: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/40.jpg)
FINAL RESULT
3.0X28mm
3.0X32mm
![Page 41: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/41.jpg)
FINAL RESULT
After 1 month PCI LAD/Cx
2.5X24mm
2.75X20mm
2.75X20mm
![Page 42: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/42.jpg)
9 MONTHS
FOLLOW-UP
![Page 43: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/43.jpg)
CASE 04: Left Main PCI
![Page 44: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/44.jpg)
FINAL RESULT
3.5X20mm
Kissing balloon
![Page 45: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/45.jpg)
10 MONTHS FOLLOW-UP
![Page 46: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/46.jpg)
CASE 05: Long lesion-Severe calcification
![Page 47: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/47.jpg)
2.75X28mm ,
3.0X32mm Stent length 60mm
Rotablator Bur size 1.5mm
![Page 48: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/48.jpg)
FINAL RESULT
![Page 49: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/49.jpg)
2.75Χ24mm
![Page 50: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/50.jpg)
FINAL RESULT 9 MONTHS FOLLOW-UP
![Page 51: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/51.jpg)
9 MONTHS FOLLOW-UP
![Page 52: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/52.jpg)
Platinum chromium stent represents an improved version
of a newer stent generation, with advantages of enhanced
visibility, good deliverability, flexibility and radial strength.
Our early experience has been very encouraging as
Promus Element has the same efficacy comparable to
other drug-eluting stents and low rates of stent thrombosis
and target lesion revascularization.
Promus Element™ has the potential to be the ‘best’ DES,
combining the established efficacy and safety of the
everolimus/polymer platform (SPIRIT data) and the
innovative design of the platinum chromium thin strut
Element™ stent
CONCLUSIONS
![Page 53: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/53.jpg)
Can we have the right
tool to do the job ?
Thank you !
![Page 54: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/54.jpg)
![Page 55: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/55.jpg)
Stent Deformation Illustration
Secondary
device catches
on mal-apposed
proximal end of
implanted stent
Stent mal-apposed
on proximal end
Guidewire biased to
mal-apposed side
Illustration for information purposes, not indicative of actual size or clinical outcome.
![Page 56: D. DIMITRIADIS · Baseline Demographics December 2009 to February 2011 n=234 Age (yrs) 64.4 ±11.3 Males 181 (77%) Diabetes Mellitus 55 (23.5%) Hypertension 132 (56.4%)](https://reader034.vdocuments.us/reader034/viewer/2022051915/60070df475fa8054714c04aa/html5/thumbnails/56.jpg)
Stenting technique remains key to positive outcomes.
Care must be exercised when crossing a newly deployed
stent with any wire, catheter or ancillary device to avoid
disrupting the stent placement, apposition, geometry,
and/or coating.
Ensure proper apposition of the stent prior to re-crossing.
Avoid deep seating the guide catheter.
Minimize wire bias where possible.
Ensure the stent is deployed to at least nominal pressure*
Most stent deformation can be addressed by using a post-
dilatation balloon.